Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu
dc.contributor.author | Kim, Myung-Ho | |
dc.contributor.author | Sise, Meghan E. | |
dc.contributor.author | Xu, Min | |
dc.contributor.author | Goldberg, David S. | |
dc.contributor.author | Fontana, Robert J. | |
dc.contributor.author | Kort, Jens J. | |
dc.contributor.author | Alloway, Rita R. | |
dc.contributor.author | Durand, Christine M. | |
dc.contributor.author | Brown, Robert S. | |
dc.contributor.author | Levitsky, Josh | |
dc.contributor.author | Gustafson, Jenna L. | |
dc.contributor.author | Reese, Peter P. | |
dc.contributor.author | Chung, Raymond T. | |
dc.date.accessioned | 2023-05-01T19:11:46Z | |
dc.date.available | 2024-05-01 15:11:45 | en |
dc.date.available | 2023-05-01T19:11:46Z | |
dc.date.issued | 2023-04 | |
dc.identifier.citation | Kim, Myung-Ho ; Sise, Meghan E.; Xu, Min; Goldberg, David S.; Fontana, Robert J.; Kort, Jens J.; Alloway, Rita R.; Durand, Christine M.; Brown, Robert S.; Levitsky, Josh; Gustafson, Jenna L.; Reese, Peter P.; Chung, Raymond T. (2023). "Early initiation of glecaprevir/pibrentasvir after transplantation of HCV- viremic kidneys into HCV- negative recipients is associated with normalization in the altered inflammatory milieu." Clinical Transplantation 37(4): n/a-n/a. | |
dc.identifier.issn | 0902-0063 | |
dc.identifier.issn | 1399-0012 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/176299 | |
dc.description.abstract | Our previous Multicenter Trial to Transplant HCV-infected Kidneys (MYTHIC) observed that 100% of hepatitis C virus (HCV)-uninfected patients who received a kidney from an HCV-infected deceased donor were cured of HCV with an 8-week regimen of glecaprevir and pibrentasvir (G/P) initiated 2–5 days after transplantation. Following acute and chronic infection with HCV, immune system perturbations have been reported to persist even after viral clearance. The aim of this study was to determine whether HCV viremic kidney recipients in the MYTHIC study experience sustained changes in the soluble inflammatory milieu associated with HCV infection. Among nine patients with HCV viremia at day 3 post-kidney transplant (post-KT D3), IP-10, IL-10, MIP-1β, and IL-8 were significantly elevated from baseline. However, over the subsequent visits, there was a rapid, dramatic reduction back to baseline levels. Among seven patients who were not HCV viremic at post-KT D3, the cytokine levels did not significantly change. HCV-uninfected patients who received a kidney from an HCV-viremic deceased donor and were treated with early G/P experienced only transient alterations in the soluble inflammatory milieu. These data provide reassuring evidence that there appear to be no persistent cytokine disturbances with transient HCV viremia accompanying HCV donor positive/recipient negative kidney transplant. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | biomarker | |
dc.subject.other | immune regulation | |
dc.subject.other | infection and infectious agents | |
dc.subject.other | viral: hepatitis C | |
dc.title | Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Medicine (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/176299/1/ctr14926-sup-0001-SuppMat.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/176299/2/ctr14926.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/176299/3/ctr14926_am.pdf | |
dc.identifier.doi | 10.1111/ctr.14926 | |
dc.identifier.source | Clinical Transplantation | |
dc.identifier.citedreference | Schachtner T, Stein M, Babel N, Reinke P. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015; 15 ( 8 ): 2159 - 2169. | |
dc.identifier.citedreference | US Department of Health and Human Services. Health Resources and Services Administration (HRSA) organ procurement transplant network. National data. Accessed August 22, 2022. https://optn.transplant.hrsa.gov/data/ | |
dc.identifier.citedreference | Roth D, Ladino M. Transplantation of kidneys from HCV-positive donors: how to best use a scarce resource. J Am Soc Nephrol. 2017; 28 ( 11 ): 3139 - 3141. | |
dc.identifier.citedreference | Schaubel DE, Tran AH, Abt PL, Potluri VS, Goldberg DS, Reese PP. Five-year allograft survival for recipients of kidney transplants from hepatitis C virus infected vs uninfected deceased donors in the direct-acting antiviral therapy era. JAMA. 2022; 328 ( 11 ): 1102 - 1104. | |
dc.identifier.citedreference | Khera T, Du Y, Todt D, et al. Long-lasting imprint in the soluble inflammatory milieu despite early treatment of acute symptomatic hepatitis C. J Infect Dis. 2021; 226: 441 - 452. | |
dc.identifier.citedreference | Hengst J, Falk CS, Schlaphoff V, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis. 2016; 214 ( 12 ): 1965 - 1974. | |
dc.identifier.citedreference | Seifert ME, Agarwal G, Bernard M, et al. Impact of subclinical borderline inflammation on kidney transplant outcomes. Transplant Direct. 2021; 7 ( 2 ): e663. | |
dc.identifier.citedreference | Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev. 2017; 30 ( 2 ): 503 - 528. | |
dc.identifier.citedreference | Molnar MZ, Potluri VS, Schaubel DE, et al. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant. 2022; 22 ( 2 ): 599 - 609. | |
dc.identifier.citedreference | Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019; 19 ( 11 ): 3046 - 3057. | |
dc.identifier.citedreference | Sise ME, Goldberg DS, Kort JJ, et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): an open-label study of combined Glecaprevir and Pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020; 31 ( 11 ): 2678 - 2687. | |
dc.identifier.citedreference | Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma. Immune Netw. 2018; 18 ( 5 ): e33. | |
dc.identifier.citedreference | Aarreberg LD, Wilkins C, Ramos HJ, et al. Interleukin-1β signaling in dendritic cells induces antiviral interferon responses. mBio. 2018; 9 ( 2 ): e00342 - 18. | |
dc.identifier.citedreference | Orzalli MH, Smith A, Jurado KA, Iwasaki A, Garlick JA, Kagan JC. An antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication. Mol Cell. 2018; 71 ( 5 ): 825 - 840. | |
dc.identifier.citedreference | Lee A, Park SP, Park CH, et al. IL-4 induced innate CD8+ T cells control persistent viral infection. PLoS Pathog. 2015; 11 ( 10 ): e1005193. | |
dc.identifier.citedreference | Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Interleukin-17—a multifaceted cytokine in viral infections. J Cell Physiol. 2021; 236 ( 12 ): 8000 - 8019. | |
dc.identifier.citedreference | Abend JR, Low JA, Imperiale MJ. Inhibitory effect of gamma interferon on BK virus gene expression and replication. J Virol. 2007; 81 ( 1 ): 272 - 279. | |
dc.identifier.citedreference | Sadeghi M, Daniel V, Schnitzler P, et al. Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation. 2009; 88 ( 9 ): 1109 - 1116. | |
dc.identifier.citedreference | Perez S, Kaspi A, Domovitz T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019; 15 ( 6 ): e1008181. | |
dc.identifier.citedreference | Hlady RA, Zhao X, El Khoury LY, et al. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology. 2022; 75 ( 4 ): 983 - 996. | |
dc.identifier.citedreference | Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated view on kidney transplant from HCV-infected donors and DAAs. Pharmaceutics. 2021; 13 ( 4 ): 496. | |
dc.identifier.citedreference | Mota AP, Vilaça SS. Cytokines signatures in short and long-term stable renal transplanted patients. Cytokine. 2013; 62 ( 2 ): 302 - 309. | |
dc.identifier.citedreference | Ito A, Sugimura J, Matsuura T, Abe T, Obara W. Plasma cytokine levels before and 1 year after successful living-donor renal transplantation. Renal Replace Ther. 2020; 6 ( 1 ): 48. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.